Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KEITH A LERRO

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1730161092
CMS profile
169870
Location
WILSON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$10,263.73

220 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $4,939.07 212
Consulting Fee $4,500.00 1
Travel and Lodging $591.16 2
Education $233.50 5

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
SUN PHARMACEUTICAL INDUSTRIES INC. $5,144.62 6
Exelixis Inc. $546.25 3
Merck Sharp & Dohme LLC $441.44 13
Novartis Pharmaceuticals Corporation $270.23 19
Celgene Corporation $220.88 12
Seagen Inc. $198.53 10
PFIZER INC. $185.98 11
Janssen Biotech, Inc. $179.44 9
E.R. Squibb & Sons, L.L.C. $179.07 6
Daiichi Sankyo Inc. $172.78 9
Incyte Corporation $166.76 7
Pharmacosmos Therapeutics Inc. $163.91 4
Dendreon Pharmaceuticals LLC $161.69 8
Amgen Inc. $140.28 9
GENZYME CORPORATION $131.86 5
ASD Specialty Healthcare, LLC $131.26 3
Pharmacyclics LLC, An AbbVie Company $114.02 2
Adaptive Biotechnologies Corporation $104.21 2
Genentech USA, Inc. $95.62 4
ABBVIE INC. $94.49 2
Gilead Sciences, Inc. $86.78 6
Alexion Pharmaceuticals, Inc. $82.35 4
CTI BioPharma Corp. $71.54 4
Bayer Healthcare Pharmaceuticals Inc. $67.24 4
Eisai Inc. $65.96 3
GlaxoSmithKline, LLC. $60.13 3
AstraZeneca Pharmaceuticals LP $53.40 3
Lilly USA, LLC $51.57 3
Boehringer Ingelheim Pharmaceuticals, Inc. $47.88 2
Stemline Therapeutics Inc. $46.75 2
AVEO Pharmaceuticals, Inc. $46.38 2
Alnylam Pharmaceuticals Inc. $42.00 2
Regeneron Healthcare Solutions, Inc. $41.38 2
Novocure Inc. $39.54 2
SERVIER PHARMACEUTICALS LLC $38.60 2
Puma Biotechnology, Inc. $38.32 2
BeiGene USA, Inc. $37.45 2
Kite Pharma, Inc. $34.34 2
RECORDATI_RARE_DISEASES_INC. $33.78 1
Rigel Pharmaceuticals, Inc. $33.74 2
PharmaEssentia USA Corporation $33.33 2
Celltrion USA Inc. $32.95 2
ARRAY BIOPHARMA INC $31.39 2
Organon LLC $30.41 1
Takeda Pharmaceuticals U.S.A., Inc. $28.47 1
Amneal Pharmaceuticals LLC $24.50 1
G1 Therapeutics, Inc. $23.40 1
MorphoSys, US Inc. $22.77 1
TAIHO ONCOLOGY, INC. $18.90 1
Mirati Therapeutics, Inc. $18.07 1
Deciphera Pharmaceuticals Inc. $16.25 1
SOBI, INC $16.10 1
ImmunoGen, Inc. $16.07 1
ADC Therapeutics America, Inc. $14.78 1
Blueprint Medicines Corporation $14.70 1
Jazz Pharmaceuticals Inc. $14.39 1
Cumberland Pharmaceuticals, Inc. $14.07 1
Karyopharm Therapeutics Inc. $14.06 1
Foundation Medicine, Inc. $13.78 1
Janssen Pharmaceuticals, Inc $2.89 1

Page 3 of 5; records 101–150 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KEITH A LERRO

NPI 1730161092 · CMS profile ID 169870

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

WILSON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1730161092?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KEITH A LERRO, NPI 1730161092, CMS profile ID 169870. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730161092?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). KEITH A LERRO, NPI 1730161092, CMS profile ID 169870. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730161092?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
KEITH A LERRO, NPI 1730161092, CMS profile ID 169870, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1730161092?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

220 matching records · $10,263.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 220 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 220.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $23.7707/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049845257 CMS
E.R. Squibb & Sons, L.L.C. $13.7807/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015943505 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $25.2907/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996637601 CMS
PFIZER INC. $16.5607/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049452661 CMS
Janssen Biotech, Inc. $17.1607/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988713457 CMS
Daiichi Sankyo Inc. $29.0907/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006407309 CMS
Adaptive Biotechnologies Corporation $86.1907/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022975833 CMS
Eisai Inc. $23.5207/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023318103 CMS
Pharmacosmos Therapeutics Inc. $25.3607/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046254677 CMS
Alnylam Pharmaceuticals Inc. $23.8807/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006174633 CMS
Mirati Therapeutics, Inc. $18.0707/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057996153 CMS
SOBI, INC $16.1007/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038109413 CMS
Celgene Corporation $17.0106/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015943489 CMS
E.R. Squibb & Sons, L.L.C. $14.7506/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015943485 CMS
Eisai Inc. $18.5306/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023318105 CMS
Celgene Corporation $20.0206/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015943493 CMS
Dendreon Pharmaceuticals LLC $18.8606/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060287427 CMS
Merck Sharp & Dohme LLC $69.5006/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048279761 CMS
Janssen Biotech, Inc. $35.8406/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988713463 CMS
Genentech USA, Inc. $26.2606/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040425149 CMS
Blueprint Medicines Corporation $14.7006/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051263277 CMS
Celgene Corporation $22.6606/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015943481 CMS
Merck Sharp & Dohme LLC $26.7006/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048278875 CMS
Gilead Sciences, Inc. $13.7606/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026028795 CMS
Novartis Pharmaceuticals Corporation $17.6306/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992235727 CMS
Novartis Pharmaceuticals Corporation $17.3706/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992235739 CMS
Amgen Inc. $16.8606/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020615363 CMS
Merck Sharp & Dohme LLC $9.5305/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048279763 CMS
Novartis Pharmaceuticals Corporation $13.3505/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992235731 CMS
Celgene Corporation $25.5105/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015943465 CMS
Alexion Pharmaceuticals, Inc. $20.7705/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017057737 CMS
Merck Sharp & Dohme LLC $16.1205/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048723009 CMS
Seagen Inc. $16.2705/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995674695 CMS
Seagen Inc. $2.3805/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995674709 CMS
E.R. Squibb & Sons, L.L.C. $13.3705/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015943461 CMS
Dendreon Pharmaceuticals LLC $16.7205/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060287425 CMS
PFIZER INC. $17.5305/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050569323 CMS
G1 Therapeutics, Inc. $23.4005/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059918427 CMS
Adaptive Biotechnologies Corporation $18.0205/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022975831 CMS
Novartis Pharmaceuticals Corporation $14.9505/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992235735 CMS
Bayer Healthcare Pharmaceuticals Inc. $20.1805/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000512171 CMS
Karyopharm Therapeutics Inc. $14.0605/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056903545 CMS
Seagen Inc. $8.8605/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995674625 CMS
Merck Sharp & Dohme LLC $29.0205/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048279769 CMS
Novartis Pharmaceuticals Corporation $14.0505/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992235719 CMS
BeiGene USA, Inc. $17.6104/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051187783 CMS
Exelixis Inc. $14.7904/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044544311 CMS
Lilly USA, LLC $19.5404/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031848743 CMS
Kite Pharma, Inc. $14.5004/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025270887 CMS
Bayer Healthcare Pharmaceuticals Inc. $13.3404/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000500079 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $34,315.17 231
PY2020 $4,384.74 174
PY2021 $9,727.25 207
PY2022 $7,162.75 221
PY2023 $10,263.73 220
PY2024 $9,068.39 214
PY2025 $4,640.33 188

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $421,529.93 32
PY2024 Recipient $1,386.05 1
PY2024 Principal investigator $357,799.31 10
PY2021 Principal investigator $3,500.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

32 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $7,410.00 12/22/2025 Non-covered Recipient Entity
SARGON RESEARCH LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175336142
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $300.00 12/16/2025 Non-covered Recipient Entity
Sargon Research LLC
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220810320
Principal investigator 1 Novartis Pharmaceuticals Corporation $175.00 12/15/2025 Non-covered Recipient Entity
REGIONAL MEDICAL ONCOLOGY CENTER
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) No dispute reported 06/30/2026 1190313903
Principal investigator 1 Epizyme, Inc. $62.80 11/12/2025 Non-covered Recipient Entity
Regional Medical Oncology Center
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184282937
Principal investigator 1 Epizyme, Inc. $78.00 11/12/2025 Non-covered Recipient Entity
Regional Medical Oncology Center
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184282939
Principal investigator 1 PFIZER INC. $47,181.76 11/12/2025 Non-covered Recipient Entity
Regional Medical Onco Center
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRSTLINE TREATMENT IN PARTICIPANTS WITH PDL1 HIGH 50 OF TUMOR CELLS EXPRESSING PDL1 LOCALLY ADVANCED UNRESECTABLE OR METASTATIC NONSMALL CELL LUNG CANCER BE6A LUNG02 No dispute reported 06/30/2026 1228713154
Principal investigator 1 Exelixis Inc. $5,000.00 11/06/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384837
Principal investigator 1 Exelixis Inc. $2,000.00 11/06/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384839
Principal investigator 1 Exelixis Inc. $5,000.00 11/06/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384841
Principal investigator 1 Janssen Research & Development, LLC $12,854.00 11/03/2025 Non-covered Recipient Entity
SARGON RESEARCH LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175336136
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $271.52 10/27/2025 Non-covered Recipient Entity
Regional Medical Oncology Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998925
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $119.88 10/27/2025 Non-covered Recipient Entity
Regional Medical Oncology Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998927
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $8.76 10/27/2025 Non-covered Recipient Entity
Regional Medical Oncology Center
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220998929
Principal investigator 1 PFIZER INC. $47,181.76 09/30/2025 Non-covered Recipient Entity
Regional Medical Onco Center
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRSTLINE TREATMENT IN PARTICIPANTS WITH PDL1 HIGH 50 OF TUMOR CELLS EXPRESSING PDL1 LOCALLY ADVANCED UNRESECTABLE OR METASTATIC NONSMALL CELL LUNG CANCER BE6A LUNG02 No dispute reported 06/30/2026 1228713336
Principal investigator 1 PFIZER INC. $47,181.76 09/02/2025 Non-covered Recipient Entity
Regional Medical Onco Center
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRSTLINE TREATMENT IN PARTICIPANTS WITH PDL1 HIGH 50 OF TUMOR CELLS EXPRESSING PDL1 LOCALLY ADVANCED UNRESECTABLE OR METASTATIC NONSMALL CELL LUNG CANCER BE6A LUNG02 No dispute reported 06/30/2026 1228713334
Principal investigator 1 Janssen Research & Development, LLC $21,836.00 09/01/2025 Non-covered Recipient Entity
SARGON RESEARCH LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175336129
Principal investigator 1 AstraZeneca UK Limited $18,250.00 08/14/2025 Non-covered Recipient Entity
SARGON RESEARCH SUMMIT LLC
phase two open label single arm trial of pirtobrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma after first line acalabrutinib progression No dispute reported 06/30/2026 1185555107
Principal investigator 1 Exelixis Inc. $500.00 05/21/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384833
Principal investigator 1 Exelixis Inc. $500.00 05/16/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384831
Principal investigator 1 Exelixis Inc. $500.00 05/16/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384835
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,500.00 03/07/2025 Non-covered Recipient Entity
Sargon Research LLC
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220810318
Principal investigator 1 Eli Lilly and Company $163,746.93 01/22/2025 Non-covered Recipient Entity
SARGON RESEARCH LLC
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) No dispute reported 06/30/2026 1187888242
Principal investigator 1 Exelixis Inc. $1,250.00 01/10/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384813
Principal investigator 1 Exelixis Inc. $1,000.00 01/10/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384815
Principal investigator 1 Exelixis Inc. $18,000.00 01/10/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384817
Principal investigator 1 Exelixis Inc. $1,500.00 01/10/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384821
Principal investigator 1 Exelixis Inc. $1,043.00 01/10/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384823
Principal investigator 1 Exelixis Inc. $3,000.00 01/10/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384825
Principal investigator 1 Exelixis Inc. $650.00 01/10/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384827
Principal investigator 1 Exelixis Inc. $900.00 01/10/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384829
Principal investigator 1 Eli Lilly and Company $1,028.76 01/09/2025 Non-covered Recipient Entity
SARGON RESEARCH LLC
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) No dispute reported 06/30/2026 1187887836
Principal investigator 1 Exelixis Inc. $1,500.00 01/03/2025 Non-covered Recipient Entity
Sargon Research LLC
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma No dispute reported 06/30/2026 1222384819